JP2024537284A5 - - Google Patents
Info
- Publication number
- JP2024537284A5 JP2024537284A5 JP2024521784A JP2024521784A JP2024537284A5 JP 2024537284 A5 JP2024537284 A5 JP 2024537284A5 JP 2024521784 A JP2024521784 A JP 2024521784A JP 2024521784 A JP2024521784 A JP 2024521784A JP 2024537284 A5 JP2024537284 A5 JP 2024537284A5
- Authority
- JP
- Japan
- Prior art keywords
- antigen
- antibody
- binding fragment
- use according
- seq
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163254447P | 2021-10-11 | 2021-10-11 | |
| US63/254,447 | 2021-10-11 | ||
| PCT/US2022/077908 WO2023064769A1 (en) | 2021-10-11 | 2022-10-11 | Methods of effecting a hemodynamic change by administering an anti-npr1 antibody |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024537284A JP2024537284A (ja) | 2024-10-10 |
| JP2024537284A5 true JP2024537284A5 (enExample) | 2025-12-22 |
Family
ID=84045029
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024521784A Pending JP2024537284A (ja) | 2021-10-11 | 2022-10-11 | 抗ｎｐｒ１抗体を投与することにより血行動態の変化を引き起こす方法 |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US20240327539A1 (enExample) |
| EP (1) | EP4415820A1 (enExample) |
| JP (1) | JP2024537284A (enExample) |
| KR (1) | KR20240099275A (enExample) |
| CN (1) | CN118159290A (enExample) |
| AU (1) | AU2022363841A1 (enExample) |
| CA (1) | CA3234238A1 (enExample) |
| CL (1) | CL2024001071A1 (enExample) |
| CO (1) | CO2024005662A2 (enExample) |
| IL (1) | IL311917A (enExample) |
| MX (1) | MX2024004302A (enExample) |
| WO (1) | WO2023064769A1 (enExample) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2023107957A1 (en) | 2021-12-06 | 2023-06-15 | Regeneron Pharmaceuticals, Inc. | Antagonist anti-npr1 antibodies and methods of use thereof |
| AU2024287056A1 (en) * | 2023-06-08 | 2025-12-11 | Jiangsu Hengrui Pharmaceuticals Co., Ltd. | Anti-npr1 antibody and pharmaceutical use thereof |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8257740B1 (en) | 2011-08-15 | 2012-09-04 | Gp Medical, Inc. | Pharmaceutical composition of nanoparticles |
| US8246995B2 (en) | 2005-05-10 | 2012-08-21 | The Board Of Trustees Of The Leland Stanford Junior University | Hydrophobic nanotubes and nanoparticles as transporters for the delivery of drugs into cells |
| EP2370098A4 (en) | 2008-12-03 | 2013-07-17 | Morphosys Ag | Antibodies for guanylyl cyclase receptors |
| CA3115102A1 (en) | 2018-10-23 | 2020-04-30 | Regeneron Pharmaceuticals, Inc. | Anti-npr1 antibodies and uses thereof |
| PH12021553101A1 (en) * | 2019-06-12 | 2023-10-02 | Novartis Ag | Natriuretic peptide receptor 1 antibodies and methods of use |
| US12325752B2 (en) * | 2020-12-18 | 2025-06-10 | Regeneron Pharmaceuticals, Inc. | Immunoglobulin proteins that bind to NPR1 agonists |
-
2022
- 2022-10-11 US US18/045,671 patent/US20240327539A1/en not_active Abandoned
- 2022-10-11 KR KR1020247015704A patent/KR20240099275A/ko active Pending
- 2022-10-11 EP EP22798040.6A patent/EP4415820A1/en active Pending
- 2022-10-11 MX MX2024004302A patent/MX2024004302A/es unknown
- 2022-10-11 WO PCT/US2022/077908 patent/WO2023064769A1/en not_active Ceased
- 2022-10-11 CN CN202280068577.9A patent/CN118159290A/zh active Pending
- 2022-10-11 IL IL311917A patent/IL311917A/en unknown
- 2022-10-11 JP JP2024521784A patent/JP2024537284A/ja active Pending
- 2022-10-11 AU AU2022363841A patent/AU2022363841A1/en active Pending
- 2022-10-11 CA CA3234238A patent/CA3234238A1/en active Pending
-
2024
- 2024-04-10 CL CL2024001071A patent/CL2024001071A1/es unknown
- 2024-04-30 CO CONC2024/0005662A patent/CO2024005662A2/es unknown
- 2024-10-11 US US18/913,899 patent/US20250034279A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2361917T3 (es) | Inhibidores del receptor 1 del factor de crecimiento de fibroblastos y procedimiento de tratamiento de los mismos. | |
| DK1976886T3 (en) | Means and methods for the treatment of tumor diseases | |
| US20210221894A1 (en) | Proteins binding nkg2d, cd16 and an antigen associated with tumors, mdscs and/or tams | |
| US20230203202A1 (en) | Proteins binding nkg2d, cd16 and 5t4 | |
| TW201023855A (en) | Antitumor combinations containing antibodies recognizing specifically CD38 and melphalan | |
| CN117222663A (zh) | 使用结合nkg2d、cd16和肿瘤相关抗原的多特异性结合蛋白治疗癌症的方法 | |
| CN114558129A (zh) | 用于降低心血管风险的方法 | |
| JP2022505604A5 (enExample) | ||
| RU2014106652A (ru) | Ингибирующие моноклональные антитела против фактора xii/xiia и их применения | |
| NO20170737A1 (no) | Anvendelse av anti-CD3 antistoff for fremstilling av et medikament mot aterosklerose, samt et anti-CD3 antistoff | |
| JP2018515513A (ja) | 多発性骨髄腫（ｍｍ）の処置 | |
| WO2023061472A1 (zh) | 抗her2抗体药物偶联物和酪氨酸激酶抑制剂联合在制备治疗肿瘤的药物中的用途 | |
| JP2023507795A5 (enExample) | ||
| JP2023155262A (ja) | プレクチン１結合抗体およびその使用 | |
| JP2025509304A5 (enExample) | ||
| CN116712539A (zh) | 抗her2抗体药物偶联物和抗pd-1抗体联合在制备治疗肿瘤的药物中的用途 | |
| JP5068253B2 (ja) | 心臓血管疾患の治療 | |
| JP2024542823A5 (enExample) | ||
| JP2024537284A (ja) | 抗ｎｐｒ１抗体を投与することにより血行動態の変化を引き起こす方法 | |
| JP2024500322A (ja) | 併用療法 | |
| WO2025134049A1 (en) | Trispecific antibody targeting bcma, gprc5d and cd3 for the treatment of al amyloidosis | |
| WO2025134050A1 (en) | Trispecific antibody targeting bcma, gprc5d and cd3 for the treatment of multiple myeloma | |
| JP2024177399A (ja) | 呼吸器疾患の治療のための汎ｅｌｒ＋ｃｘｃケモカイン抗体 | |
| JP2023506779A5 (enExample) | ||
| WO2017064034A1 (en) | An agent capable of depleting cd8 t cells for the treatment of myocardial infarction or acute myocardial infarction |